Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Rossari Biotech Ltd

| Consolidated Financial Results for Q4 and Year Ended March 31, 2026

Report Source

⬤27th Apr 26

Summary : Rossari Biotech reports strong FY26 financials, declares dividend, and advances R&D.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Consolidated Total Expenses: ₹22,181.29 million (FY26) vs ₹19,000.96 million (FY25).
  2. Standalone Total Expenses: ₹15,880.13 million (FY26) vs ₹12,826.67 million (FY25).
  3. Consolidated Revenue from operations: ₹23,963.65 million (FY26) vs ₹20,802.94 million (FY25).
  4. Standalone Revenue from operations: ₹17,520.66 million (FY26) vs ₹14,316.28 million (FY25).
  5. Consolidated Net cash from operating activities: ₹650.68 million (FY26) vs ₹1,374.43 million (FY25).
  6. Consolidated Net cash used in investing activities: ₹(2,194.81) million (FY26) vs ₹(1,836.95) million (FY25).
  7. Consolidated Net cash from financing activities: ₹1,863.22 million (FY26) vs ₹649.01 million (FY25).
  8. Standalone Net cash from operating activities: ₹587.29 million (FY26) vs ₹921.98 million (FY25).
  9. Standalone Net cash used in investing activities: ₹(1,014.04) million (FY26) vs ₹(699.17) million (FY25).
  10. Standalone Net cash from financing activities: ₹791.29 million (FY26) vs ₹(322.73) million (FY25).
  11. Consolidated Total Assets: ₹22,887.92 million (FY26) vs ₹18,961.84 million (FY25).
  12. Consolidated Total Equity: ₹13,333.49 million (FY26) vs ₹11,854.49 million (FY25).
  13. Standalone Total Assets: ₹17,636.36 million (FY26) vs ₹14,509.21 million (FY25).
  14. Standalone Total Equity: ₹12,184.94 million (FY26) vs ₹10,771.74 million (FY25).
  15. Both standalone and consolidated financial results are presented and audited.
  16. Consolidated results include 8 subsidiaries, 2 step-down subsidiaries, 1 joint venture, and 1 associate.

Corporate Overview

  1. India (Mumbai, Silvassa, Dahej).
  2. Foreign subsidiaries (UAE, Bangladesh, Singapore).
  3. International operations through joint ventures and associates.
  4. Re-evaluating capacity expansion due to evolving business requirements and market conditions.
  5. Specialty chemicals manufacturing and distribution.
  6. Products for Home, Personal Care, Performance Chemicals.
  7. Textile Speciality Chemicals.
  8. Animal Health and Nutrition.
  9. Factual and compliant in reporting financial results and board decisions.
  10. Strategic intent for capacity expansion remains unchanged despite rescheduling.
  11. Specialty chemicals.
  12. Proposed capacity expansion project rescheduled.
  13. Expansion to be undertaken in a phased manner over two years.
  14. Capacity addition project to be undertaken in a phased manner over the next two years.
  15. Established new Research and Development Facility in Navi Mumbai.
  16. Relocated existing R&D facility to the new Navi Mumbai site.
  17. New R&D facility enhances innovation and product development.

Risk Factors

  1. Capacity expansion project rescheduled.
  2. Evolving business and market conditions.
  3. New Labour Codes impact gratuity.
  4. Reliance on other auditors' reports.

Key Drivers

  1. Strong revenue and profit growth.
  2. New R&D facility boosts innovation.
  3. Phased capacity expansion over two years.
  4. Final dividend of 25% declared.

Auditor’s Report

  1. Unmodified opinion on Standalone and Consolidated Financial Results.
  2. Consolidated results rely on other auditors' reports for subsidiaries, associate, and joint ventures.
  3. Consolidated results include unaudited financial information for two subsidiaries, deemed not material.

Board Commentary

  1. Appointment of Mr. Udeypaul Singh Gill as Additional Non-Executive, Independent Director.
  2. Term of appointment for Mr. Gill is three consecutive years from April 28, 2026.
  3. Final Dividend of 25% (Re. 0.50/- per share) for FY 2025-26.
  4. Dividend to be paid/dispatched within 10 working days of AGM conclusion.
  5. Re-evaluation of capacity expansion due to evolving business requirements.
  6. Potential impact of new Labour Codes on future liabilities.
  7. New Labour Codes (Code on Wages, Social Security, Industrial Relations, Occupational Safety) effective from November 21, 2025.
  8. Revised gratuity liability estimated and recognized due to new Labour Codes.
  9. Capacity addition project re-evaluation and rescheduling.
  10. Establishment of a new Research and Development Facility in Navi Mumbai.

Corporate Governance

  1. Auditor's report confirms compliance with Code of Ethics and ethical requirements.
  2. Appointment of an Independent Director, Mr. Udeypaul Singh Gill.
  3. Auditor's report confirms compliance with ethical requirements and independence.
  4. Audit Committee reviewed financial results.
  5. Nomination and Remuneration Committee recommended board appointment.

Management Discussion & Analysis

Future Strategy

  1. Phased capacity expansion over the next two years.
  2. Continued focus on R&D for technological advancement.

Operational Focus Areas

  1. Implementing phased capacity expansion.
  2. Leveraging new R&D facility for product innovation.

Performance Drivers

  1. New R&D facility to drive innovation and product development.
  2. Strategic capacity expansion plans to meet market demand.

Critical Risks

  1. Rescheduling of capacity expansion project due to market conditions.
  2. Impact of new Labour Codes on gratuity liability.
Rossari Biotech Ltd (ROSSARI) Quarterly Report Analysis & Insights | Dhanarthi